About: Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis
Creator	Kumar, Ashish Sharma, Praveen Arora, Anil Bansal, Naresh Khare, Shivam Singla, Vikas Srivastava, Abhishyant Anikhindi, Anil Shrihari, &
Source	Medline; PMC
abstract	BACKGROUND: Many case series on Corona Virus Disease (COVID-19) have reported gastrointestinal (GI) and hepatic manifestations in a proportion of cases; however, the data is conflicting. The relationship of GI and hepatic involvement with severe clinical course of COVID-19 has also not been explored. OBJECTIVES: The main objectives were to determine the frequency of GI and hepatic manifestations of COVID-19 and to explore their relationship with severe clinical course. METHODS: We searched PubMed for studies published between January 1, 2020, and March 25, 2020, with data on GI and hepatic manifestations in adult patients with COVID-19. These data were compared between patients with severe and good clinical course using the random-effects model and odds ratio (OR) as the effect size. If the heterogeneity among studies was high, sensitivity analysis was performed for each outcome. RESULTS: We included 62 studies (8301 patients) in the systematic review and 26 studies (4676 patients) in the meta-analysis. Diarrhea was the most common GI symptom (9%), followed by nausea/vomiting (5%) and abdominal pain (4%). Transaminases were abnormal in approximately 25%, bilirubin in 9%, prothrombin time (PT) in 7%, and low albumin in 60%. Up to 20% patients developed severe clinical course, and GI and hepatic factors associated with severe clinical course were as follows: diarrhea (OR 2), high aspartate aminotransferase (OR 1.4), high alanine aminotransferase (OR 1.6), high bilirubin (OR 2.4), low albumin (OR 3.4), and high PT (OR 3). CONCLUSIONS: GI and hepatic involvement should be sought in patients with COVID-19 since it portends severe clinical course. The pathogenesis of GI and hepatic involvement needs to be explored in future studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12664-020-01058-3) contains supplementary material, which is available to authorized users.
has issue date	2020-08-04(xsd:dateTime)
bibo:doi	10.1007/s12664-020-01058-3
bibo:pmid	32749643
has license	no-cc
sha1sum (hex)	ea7cb77aa274d2b63f673588301482d73c5e3a0e
schema:url	https://doi.org/10.1007/s12664-020-01058-3
resource representing a document's title	Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis
has PubMed Central identifier	PMC7399358
has PubMed identifier	32749643
schema:publication	Indian J Gastroenterol
resource representing a document's body	covid:ea7cb77aa274d2b63f673588301482d73c5e3a0e#body_text
is schema:about of	named entity 'model' named entity 'severe' named entity 'MANIFESTATIONS' named entity 'FREQUENCY' named entity 'CONFLICTING' named entity 'GASTROINTESTINAL' named entity 'gastrointestinal' named entity 'odds ratio' named entity 'studies' named entity 'heterogeneity' named entity 'high' named entity 'patients' named entity 'PubMed' named entity 'good' named entity 'COVID-19' named entity 'hepatic' named entity 'COVID-19' named entity 'hepatic' named entity 'effect size' named entity 'severe' named entity 'severe' named entity 'meta-analysis' named entity 'statistical analyses' named entity 'NIHR' named entity 'comorbidities' named entity 'confounding variables' named entity 'receptor' named entity 'demographic' named entity 'AST' named entity 'cough' named entity 'meta-analyses' named entity 'serum albumin' named entity 'diarrhea' named entity 'SIRS' named entity 'corona virus' named entity 'serum' named entity 'COVID' named entity 'Serum bilirubin' named entity 'nausea' named entity 'asymptomatic' named entity 'chronic liver disease' named entity 'transaminases' named entity 'liver injury' named entity 'antiviral' named entity 'comorbidity' named entity '0.01' named entity 'bile duct' named entity 'ACE2' named entity '0.01' named entity '0.01' named entity 'COVID' named entity 'COVID-19' named entity 'hypoxia' named entity '2.04' named entity 'infection' named entity 'sample size' named entity 'Meta-Analyses' named entity 'ICU' named entity 'English language' named entity 'SARS-CoV-2' named entity 'small intestine' named entity 'confidence intervals' named entity 'clinical presentation' named entity 'liver' named entity 'PubMed' named entity 'clinical data' named entity 'NIH' named entity 'covid-19' named entity 'systematic review' named entity 'COVID' named entity 'Singapore' named entity 'infection' named entity 'drug toxicity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software